http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a737b3eb9b9578e19881124485bf54b5
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Takao Yamori Yamori |
| name | Takao Yamori |
| given-name | Takao |
| organization-name | Kobe Pharmaceutical University, 4-19-1 Motoyamakita, Higashinada-ku, Kobe 658-8558, Japan, Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 1-37-1 Kamiikebukuro, Toyoshima-ku, Tokyo 170-8455, Japan, Institute of Molecular and Cellular Biosciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-0000, Japan, Department of Biochemistry, College of Natural Science, Dongguk University, Kyongju Kyongbuk 780-714, Korea, and Institute of Pharmacy,... Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi 467-8603, Japan, Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan, Division of Organic Chemistry, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan, and Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-10-6 Ariake, Koto... Cancer Chemotherapy Center Japanese Foundation for Cancer Research Tokyo Japan 1Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research; Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan; Laboratory of Aquatic Natural Products Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-8657, Japan, Misaki Marine Biological Station, The University of Tokyo, Miura, Kanagawa 238-0225, Japan, Takehara Marine Science Station, Hiroshima University, Takehara, Hiroshima 725-0024, Japan, and Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Koto-ku, Ariake, Tokyo 135-8550, Japan 1Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan. Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-10-6 Ariake, Koto-ku, Tokyo 135-8550, Japan. Authors' Affiliations: 1Department of Neurological Surgery, Dardinger, Center for Neuro-oncology, James Cancer Hospital and The Ohio State University, Columbus, Ohio; 2Division of Molecular Biotherapy, 3Division of Molecular Pharmacology, Cancer Chemotherapy, Center of Japanese Foundation for Cancer Research; and 4National Institute of Advanced Industrial Science and Technology, Tokyo, Japan 3Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Toshima-ku, Tokyo 170-8455, Japan Division of Molecular Pharmacology Cancer Chemotherapy Center Japanese Foundation for Cancer Research Tokyo Japan Authors' Affiliations: 1Université Victor Segalen Bordeaux 2, INSERM U916 and Institut Bergonié, Bordeaux, France; and 2Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan Division of Molecular pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research; Center for Product Evaluation, Pharmaceuticals and Medical Devices Agency Authors' Affiliations: 1Division of Medical Oncology; 2Division of Tumor Dynamics and Regulation, Cancer Research Institute, Kanazawa University, Kanazawa; 3Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo; 4Department of Respiratory Medicine & Rheumatology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan Laboratory of Bioorganic Chemistry, School of Life Science, Tokyo University of Pharmacy and Life Science, Horinouchi, Hachioji, Tokyo 192-0392, Japan, and Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Kami-ikebukuro, Toshima, Tokyo 170-8455, Japan yamori@jfcr.or.jp Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan Division of Molecular Pharmacology, Cancer Chemotherapy Center Japanese Foundation for Cancer Research 3‐8‐31 Ariake Koto‐ku 135‐8550 Tokyo Japan Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan 2Center for Product Evaluation, Pharmaceuticals and Medical Device Agency, Tokyo, Japan. Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-10-6 Ariake, Koto-ku, Tokyo 135-8550, Japan Laboratory of Medicinal Pharmacognosy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Horinouchi 1432-1, Hachiouji, Tokyo 192-0392, Japan, and Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-10-6, Ariake, Koutou-ku, Tokyo 135-8550, Japan Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan, and Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 1-37-1 Kami-Ikebukuro, Toshima-ku, Tokyo 170-8455, Japan Molecular Pharmacology Cancer Chemotherapy Center Japanese Foundation for Cancer Research Tokyo Japan Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan Cancer Therapy Center, Japanese Foundation for Cancer Research Authors' Affiliations: 1Massachusetts General Hospital Cancer Center; 2Department of Medicine, Harvard Medical School, Boston, Massachusetts; Divisions of 3Experimental Chemotherapy and 4Molecular Pharmacology, Cancer Chemotherapy Center, Japanese foundation for Cancer Research; 5Department of Medical Genome Sciences, Graduate School of Frontier Sciences, The University of Tokyo; and 6Pharmaceuticals and Medical Devices Agency (PMDA), Tokyo, Japan; Authors' Affiliations: 1Massachusetts General Hospital Cancer Center; 2Department of Medicine, Harvard Medical School, Boston, Massachusetts; Divisions of 3Experimental Chemotherapy and 4Molecular Pharmacology, Cancer Chemotherapy Center, Japanese foundation for Cancer Research; 5Department of Medical Genome Sciences, Graduate School of Frontier Sciences, The University of Tokyo; and 6Pharmaceuticals and Medical Devices Agency (PMDA), Tokyo, Japan Department of Medicinal Chemistry, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan, and Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 1-37-1 Kami-Ikebukuro, Toshima-ku, Tokyo 170-8455, Japan Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research. Cancer Chemotherapy Center, Japanese Foundation for Cancer Research Division of Molecular Pharmacology Cancer Chemotherapy Center Japanese Foundation for Cancer Research 3‐8‐31 Ariake Koto‐ku Tokyo 135‐8550 Japan; Center for Product Evaluation Pharmaceuticals and Medical Device Agency Shin‐Kasumigaseki Building 3‐3‐2 Kasumigaseki Tokyo 100‐0013 Japan School of Pharmacy, Tokyo University of Pharmacy and Life Science, 1432-1, Horinouchi, Hachioji, Tokyo 192-0392, Japan, and Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 1-37-1, Kami-ikebukuro, Toshima-ku, Tokyo 170-8455, Japan Division of Molecular Pharmacology, Cancer Institute, Japanese Foundation for Cancer Research, 1-37-1 Kami-ikebukuro, Toshima-ku, Tokyo 170-8455, Japan. Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan, and Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 1-37-1 Kami-Ikebukuro, Toshima-ku, Tokyo 170-8455, Japan Division of Medical Devices,National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan. Authors' Affiliations: 1Division of Molecular Pharmacology, Cancer Chemotherapy Center, and 2Department of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan and 3Department of Biomedical Engineering, Toin Human Science and Technology Center, and 4Department of Biomedical Engineering, Toin University of Yokohama, Yokohama, Japan Graduate School of Science and Technology and Department of Chemistry and Chemical Engineering, Niigata University, Ikarashi, 2-8050, Niigata, 950-2181, Japan, Kobe Natural Products and Chemicals Co., Ltd., 527 Nishikawanabe Ichikawa-Cho Kanzaki-Gun Hyogo 679-2315, Japan, Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 1-37-1 Kami-Ikebukuro, Toshima-Ku, Tokyo 170-8455, Japan, and Institute of Molecular and Cellular Biosciences, University of Tokyo,... Pharmaceuticals and Medical Devices Agency Tokyo Japan Division of Experimental Chemotherapy, Japanese Foundation for Cancer Research, Tokyo, Japan. 7Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan and Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan; Present address: Center for Product Evaluation, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan 3Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, and |
Incoming Links
Total number of triples: 243.